Pharma Market Forecasts
The total pharmaceutical market in the Netherlands was valued at $2.28 billion in 1994 by PMSI International's 1995 Pharmaceutical Global Review, an increase of 14.5% in the previous year, when it grew only 4.3%. PMSI projects an average annual growth rate of 7.5% to the year 2000, when the market should reach a value of $3.78 billion.
The leading product categories in 1994 were as follows: Therapy group Sales +/-% $ Mill on 1993 H2 antagonists 129.4 +9.7 Corticoids inhalant 89.7 +25.5 Calcium antagonists (plain) 89.0 +24.7 ACE inhibitors 87.0 +26.6 Acid pump inhibitors 84.5 +30.9 Human insulin 70.7 +19.2 Antirheumatics (NSAID) 69.4 +10.0 Beta blockers (plain) 67.7 +13.0 Antidepressants 66.4 +45.3 B2 stimulants inhalant 64.1 +22.8 Source: PMSI International
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze